Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 IMS is releasing updates ... to the web and provide greater accessibility and ... reporting metrics increase data warehouse’s utility; plus, the ... and access “on-the-go” makes data analysis even easier. ... feedback to assist in repository analytics and business ...
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... 27, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the year ended December 31, 2014. ... dollars and presented under International Financial Reporting Standards ... results did not provide the outcome management and ... remain at iCo Therapeutics", said Andrew Rae ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 Deadly ... Therapeutics, the newest resident of the University City ... Street in Philadelphia. , With a $4.5 million ... Health in hand, Phelix Therapeutics is focused ... developing nutritional supplements. The company is developing first-in-class protease ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2
... towards building a microscopic device that can construct nano ... the peer-reviewed publication, International Journal of Nanomanufacturing from Inderscience ... , In his 1986 book, The Engines of Creation, ... nanotechnology - to create an assembler, a microscopic device, ...
... Year Period, DUBLIN, Calif., April 28 SuperGen ... the first quarter ended,March 31, 2008., Total revenues ... $4.4 million for the same prior year period. Total ... in royalty revenue, compared,with $3.8 million for the same ...
... 28 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ), ... zinc finger DNA-binding proteins (ZFPs) for therapeutic gene,regulation ... G.,Wiggans to the company,s Board of Directors., ... Officer of,Connetics Corporation, a biotechnology company, from 1994, ...
Cached Biology Technology:Are nanobots on their way? 2Are nanobots on their way? 3SuperGen Reports 2008 First Quarter Financial Results 2SuperGen Reports 2008 First Quarter Financial Results 3SuperGen Reports 2008 First Quarter Financial Results 4SuperGen Reports 2008 First Quarter Financial Results 5SuperGen Reports 2008 First Quarter Financial Results 6SuperGen Reports 2008 First Quarter Financial Results 7SuperGen Reports 2008 First Quarter Financial Results 8SuperGen Reports 2008 First Quarter Financial Results 9Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... in a way that had never been observed in ... Current Biology, a Cell Press publication. The discoverywhich marks ... to perceive circular polarized light may lend mantis shrimp ... into a new dimension of vision, said Justin Marshall ...
... minerals--mineral nanoparticles--in oceans and rivers, atmosphere and soils, ... new ways of understanding Earth,s workings. Our planet,s ... driven by the properties of these minerals. ... universities in a paper published in this week,s ...
... finches are becoming more common as pets, but the ... includes some of the most exotic creatures on the ... multi-billion dollar enterprise, but expansion of the industry sometimes ... that afflict these unusual animals. The new Manual ...
Cached Biology News:Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3'Nanominerals' influence Earth systems from ocean to atmosphere to biosphere 2Veterinarians' guide to hedgehogs, chinchillas and chelonians.....oh, my! 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: